BRAIN Biotech AG

BNN

DE0005203947

Environmental Services & Equipment

Market Closed - Xetra Other stock markets 11:36:06 2024-05-09 am EDT			Pre-market 02:35:06 am
2.75 ^EUR	+2.61%		2.85	+3.64%

Apr. 16	Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery	MT
Mar. 05	BRAIN Biotech AG and AMSilk GmbH Announce the Successful Completion of the First Phase of A Development Collaboration	CI

Presenter SpeechMichael Schneiders (Executives)Hello, and welcome, everybody, to our Q4 and fi...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about BRAIN Biotech AG

Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery	Apr. 16	MT
BRAIN Biotech AG and AMSilk GmbH Announce the Successful Completion of the First Phase of A Development Collaboration	Mar. 05	CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 28	CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 17	CI
BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-29	CI
BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-25	CI
Transcript : BRAIN Biotech AG, Q2 2023 Earnings Call, May 25, 2023	23-05-25
BRAIN Biotech to Look Acquisitions	23-05-24	CI
BRAIN Biotech AG acquired remaining 17.8% stake in Biocatalysts Limited for ?9.6 million.	23-05-23	CI
SolasCure Limited announced that it has received £10.9 million in funding from Seneca Partners Limited, BRAIN Biotech AG, Eva Pharma Consultants Ltd, Wealth Club Limited and another investor	23-03-26	CI
BRAIN Biotech AG announced that it expects to receive ?5 million in funding from MP Beteiligungs-Gmbh	23-03-07	CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-27	CI
BRAIN Biotech Ends Contract with Roquette Frères on Natural Sweetener Joint Development	23-02-10	MT
BRAIN Biotech Unit to Focus on Developing New Therapies Via Genome-editing Technology	23-01-10	MT
BRAIN Biotech AG Announces Executive Changes	23-01-08	CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2022	22-11-28	CI
La Cultura Verde Ltd. acquired LA Schmitt from BRAIN Biotech AG.	22-09-25	CI
BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-28	CI
BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-06-03	CI
Brain Biotech Ag Announces Resignation of Bernhard Hauer from Supervisory Board, as of May 31, 2022	22-05-30	CI
Brain Biotech AG Announces Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas, BRAIN-Engineered-Cas	22-04-04	CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2021	22-02-25	CI
BRAIN Biotech AG and Formo Bio GmbH Launch A Strategic Collaboration to Further Advance the Production of Animal-Free Milk Proteins	22-02-08	CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2021	22-01-17	CI
BRAIN Biotech AG Announces That It Is Extending Its Proprietary Genome-Editing Toolbox with the Addition of Brain-Metagenome-Cas 01 Nuclease	21-12-08	CI

BRAIN Biotech AG, formerly known as BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company develops and brings to market biological ingredients for Nutrition & Health, SkinCare and Industrial BioSolutions. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.

Sector

Environmental Services & Equipment

Calendar

2024-05-28 - Q2 2024 Earnings Release

More about the company